{
  "id": "61f7c883882a024a10000026",
  "type": "factoid",
  "question": "What disease can be treated with Avacopan?",
  "ideal_answer": "Avacopan is effective for ANCA-associated vasculitis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34553355",
    "http://www.ncbi.nlm.nih.gov/pubmed/34484454",
    "http://www.ncbi.nlm.nih.gov/pubmed/34473462",
    "http://www.ncbi.nlm.nih.gov/pubmed/32088663",
    "http://www.ncbi.nlm.nih.gov/pubmed/34826105",
    "http://www.ncbi.nlm.nih.gov/pubmed/34006155",
    "http://www.ncbi.nlm.nih.gov/pubmed/33164993",
    "http://www.ncbi.nlm.nih.gov/pubmed/33596356",
    "http://www.ncbi.nlm.nih.gov/pubmed/29718732",
    "http://www.ncbi.nlm.nih.gov/pubmed/33625803",
    "http://www.ncbi.nlm.nih.gov/pubmed/34224265",
    "http://www.ncbi.nlm.nih.gov/pubmed/33128347",
    "http://www.ncbi.nlm.nih.gov/pubmed/28400446"
  ],
  "snippets": [
    {
      "text": "Current therapies are often effective in inducing and maintaining remission but are associated with a range of toxicities. Several new therapies are in development for ANCA vasculitis. Avacopan, an orally administered inhibitor of the complement fragment 5a (C5a) receptor, has been assessed in a phase 3 clinical trial and may play a role in reducing the cumulative glucocorticoid dose. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34473462",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "New treatment approaches, such as the C5a receptor inhibitor avacopan could enable a\u00a0minimized steroid treatment in the future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "GPA/MPA INDUCTION OF REMISSION: \u2002As demonstrated in the ADVOCATE-trial avacopan allows for a substantial reduction of glucocorticoid (GC) use during induction of remission. A future role of avacopan in the treatment of GPA and MPA is likely.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34553355",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avacopan has shown significant promise in ANCA-associated vasculitis as part of a glucocorticoid-free induction regimen in a recently completed phase 3 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33164993",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224265",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "SOURCE CITATION: Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599-609. 33596356.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224265",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avacopan for the Treatment of ANCA-Associated Vasculitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and was superior to prednisone taper with respect to sustained remission at week 52. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28400446",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "tly, new molecules are being developed and some of them have already demonstrated clinical efficacy, such as avacopan (C5aR blocker) in ANCA vasculitis. As for k",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33625803",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ber 2021, avacopan received its first approval in Japan for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two most common forms of ANCA-associated vasculitis, where it is being commercialized by Kissei Pharmaceutical through a partnership with Vifor Pharma. In October 20",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avacopan for the treatment of ANCA-associated vasculitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34006155",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Avacopan for the Treatment of ANCA-Associated Vasculitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Avacopan in the treatment of ANCA-associated vasculitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29718732",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224265",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " avacopan was approved in the USA as an adjunctive treatment in adults for severe active ANCA-associated vasculitis (specifically MPA and GPA) in combination with standard therapy including glucocorticoids (avacopan does not eliminate glucocorticoid use). Avacopan has rece",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avacopan (TAVNEOS\u2122) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. The ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "al will evaluate if avacopan replaces the need for chronic glucocorticoids in the treatment of ANCA-associated vasculitis.OBJECTI",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32088663",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avacopan for the treatment of ANCA-associated vasculitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34006155",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Avacopan in the treatment of ANCA-associated vasculitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29718732",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with glucocorticoids with cyclophosphamide or",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33128347",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rednisone.CONCLUSIONS: In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone tap",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avacopan (TAVNEOS\u2122) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In September 2021, avacopan received its first approval in Japan for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two most common forms of ANCA-associated vasculitis, where it is being commercialized by Kissei Pharmaceutical through a partnership with Vifor Pharma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In October 2021, avacopan was approved in the USA as an adjunctive treatment in adults for severe active ANCA-associated vasculitis (specifically MPA and GPA) in combination with standard therapy including glucocorticoids (avacopan does not eliminate glucocorticoid use).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with glucocorticoids with cyclophosphamide or rituximab.METHODS: In this randomized 12-week study, twice daily avacopan (10 mg or 30 mg) plus SOC was assessed versus SOC only in patients with newly diagnosed/relapsing ANCA-as",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33128347",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "onephritis. This trial will evaluate if avacopan replaces the need for chronic glucocorticoids in the treatment of ANCA-associated vasculitis.OBJECTIVE: The aim of this study is to determine the proportions of patients in remission at week 26 and with sustained remission at week 52, defined as Birmingham Vasculitis Activity Score=0, and not taking glucocorticoids within the 4 weeks before week 26 and week 52, respectively.METHODS: The Avacopan Development in Vasculitis to Obtain Corticosteroid elimination and Therapeutic Efficacy study is a randomized, double-blind, active-comparator (prednisone), 2-arm study evaluating the safety and efficacy of avacopan versus prednisone, administered in combination with ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32088663",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ANCA-associated vasculitis"
}